PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
EHA Library, Anthony R. Mato,
325284
PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF RAVULIZUMAB IN CHILDREN AND ADOLESCENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: INTERIM ANALYSIS OF A PHASE 3, OPEN-LABEL STUDY
EHA Library, Satheesh Chonat,
325350
CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA RECEIVING CONVENTIONAL THIRD-LINE THERAPY: A MULTICENTER, RETROSPECTIVE, REAL-WORLD STUDY IN THE UNITED KINGDOM
EHA Library, Christopher Fox,
325299
BCX9930, A NOVEL ORAL FACTOR D INHIBITOR, HAS POSITIVE EFFECTS ON HEMOLYSIS AND CLINICAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAÏVE TO COMPLEMENT INHIBITORS
EHA Library, Andrew McDonald,
325345
BCX9930, AN ORAL FACTOR D INHIBITOR, CONTROLS EXTRAVASCULAR HEMOLYSIS AND ALLEVIATES ASSOCIATED SYMPTOMS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
EHA Library, Austin G. Kulasekararaj,
325349